New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A restricted ...
Please provide your email address to receive an email when new articles are posted on . Greater weight loss at 1 year with tirzepatide improved the odds for sustaining an HbA1c of 6.5% or less at 2 ...
8d
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf.
Biomea Fusion (NASDAQ:BMEA) outlined progress on its clinical-stage pipeline during an Oppenheimer virtual conference appearance featuring CEO Mick Hitchcock and COO Ramses Erdtmann. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results